BSEConcord Drugs LtdMinimalNeutral
Announced Fri, 27 Mar · 16:52 IST

Closure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March, 2026.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.3%1-day move
₹71.87
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.3-1.2+0.2-2.3-1.1+3.2+19.4+18.4+15.5+4.4
Up moveDown movePending
AI summary

Concord Drugs Limited has informed BSE that its trading window will be closed starting Wednesday, 1st April 2026, and will reopen 48 hours after the announcement of audited standalone and consolidated financial results for the quarter and financial year ending 31st March 2026. During this period, all directors, designated employees, insiders, and their immediate relatives are prohibited from trading in the company's securities. The company has confirmed that the date of the board meeting to approve the results will be communicated separately. The intimation is issued in compliance with SEBI's Insider Trading Regulations, 2015.

Likely market impact

This is a routine regulatory compliance announcement and does not directly impact shareholders. However, it signals that the company's Q4 and FY26 audited results are forthcoming, which may be a key event for investors to track. The stock could see movement once results are declared.